Michael P. Gosland - Concepedia

Concepedia

Author

Michael P. Gosland

University of Kentucky

Also Known As

M Gosland, M P Gosland, M. Gosland, MICHAEL P. GOSLAND, Michael Gosland, Michael P. Gosland

22

Publications

1.2K

Citations

16

H-Index

49

Concepts

All Affiliations

University of Kentucky Stanford University Markey Cancer Center University of the Pacific Albert B. Chandler Hospital

MP

About

Michael P. Gosland is an author at University of Kentucky specializing in medicine, pharmacology, and cell biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	11	686
2	Cell Biology	5	5	197
3	Health Sciences	4	4	145
4	Biochemistry	3	3	91
5	Cellular Physiology	1	1	23

Michael P. Gosland

×

17

Publications

1.2K

Citations

15

H-Index

	Year	Citations
Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance. B L Lum, Sonja Kaubisch, Alan M. Yahanda, Journal of Clinical Oncology Therapeutic Drug MonitoringOncologyMedicineEtoposide AucMultidrug Resistance	1992	298
Phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance. Alan M. Yahanda, K M Alder, George A. Fisher, Journal of Clinical Oncology	1992	218
MDR Expression in Normal Tissues: Pharmocologic Implication for the Clinical Use of P-Glycoprotein Inhibitors Bert L. Lum, Michael P. Gosland Hematology/Oncology Clinics of North America	1995	131
Molecular Targets in Oncology: Implications of the Multidrug Resistance Gene Bert L. Lum, Michael P. Gosland, Sonja Kaubisch, Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy	1993	92
Reversal by cefoperazone of resistance to etoposide, doxorubicin, and vinblastine in multidrug resistant human sarcoma cells. Michael P. Gosland, B L Lum, Branimir I. Šikić PubMed Lipid SolubilityTumor BiologyPharmaceutical ScienceAntibioticsMedicine	1989	75
Insights into Mechanisms of Cisplatin Resistance and Potential for Its Clinical Reversal Michael P. Gosland, Bert L. Lum, Julia Schimmelpfennig, Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy Cisplatin ResistanceChromatinTumor BiologyChromatin RemodelingMedicine	1996	68
The use of probenecid as a chemoprotector against cisplatin nephrotoxicity Charlotte Jacobs, Sonja Kaubisch, Joanne Halsey, Cancer PharmacotherapyCisplatin NephrotoxicityCumulative AucMolecular PharmacologyOncology	1991	54
Analysis of blood T‐cell cytokine expression in B‐chronic lymphocytic leukaemia: evidence for increased levels of cytoplasmic IL‐4 in resting and activated CD8 T cells Xi Mu, Neil E. Kay, Michael P. Gosland, British Journal of Haematology T-regulatory CellImmunologyPathologyCd4 T Cell ResponsesImmune System	1997	50
17 beta-estradiol glucuronide: an inducer of cholestasis and a physiological substrate for the multidrug resistance transporter. Michael P. Gosland, Clifford P. Tsuboi, Tim Hoffman, PubMed Chemoprevention StrategyLipid PeroxidationMultidrug ResistanceDrug ResistanceMolecular Pharmacology	1993	37
MDR1 substrates/modulators protect against beta-estradiol-17beta-D-glucuronide cholestasis in rat liver. Y Liu, Liyue Huang, Tim Hoffman, PubMed CholangiopathiesOxidative StressMolecular PharmacologyBolus DoseHepatotoxicity	1996	31

Page 1